Jump to content
Crime Forum

Presently, several small molecule protein degraders are being evaluated {RootsAnalysis}

Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease causing / associated proteins, using bifunctional small molecule drugs. Presently, the most popular and promising class of interventions in this field of research, is proteolysis targeting chimeras (PROTACs); these can simultaneously bind a target protein and an E3-ubiquitin ligase, and thereby, facilitate the selective ubiquitination and eventual proteasome-mediated degradation of the target protein. The most interesting feature of this mechanism of drug action is the fact that PROTACs and other targeted protein degraders can eliminate protein targets regardless of their function.


To order this 330+ page report, which features 115+ figures and 180+ tables, please visit this link


The USD 3.3 billion (by 2030) financial opportunity within the targeted protein degradation enabling technologies market has been analyzed across the following segments:

§  Type of Payment

§  Upfront Payment

§  Milestone Payment


§  Types of Protein Degraders

§  Degronimids


§  SARDs / SERDs

§  Specific BET and DUB Inhibitors

§  Other Inhibitors


§  Therapeutic Areas

  • Oncological Disorders
  • Neurological Disorders
  • Others


§  Route of Administration

§  Oral

§  Intravenous

§  Others


§  Key Geographical Regions 

§  North America

§  Europe

§  Asia-Pacific


The Targeted Protein Degradation Market, 2021-2030 report features the following companies, which we identified to be key players in this domain:

§  Arvinas

§  AstraZeneca

§  BioTheryX

§  C4 Therapeutics

§  Captor Therapeutics

§  Celgene

§  Genentech

§  Hinova Pharmaceuticals

§  Kangpu Biopharmaceuticals

§  Kymera Therapeutics

§  Mission Therapeutics

§  Progenra

§  Radius Health

§  Sanofi Genzyme

§  Zenopharm


Table of Contents


1. Preface

2. Executive Summary

3. Introduction

1.    Current Market Landscape: Target Protein Degradation-Based Therapeutics

5. Current Market Landscape: Target Protein Degradation Enabling Technologies

6. Company Profiles

7. Clinical Trial Analysis 

8. Academic Grants Analysis

9. Publication Analysis


10. Patent Analysis

11. KOL Analysis

12. Partnerships and Collaborations

13. Funding and Investment Analysis

14. Market Sizing and Opportunity Analysis


15. Licensing Deal Structure


16. Executive Insights


17. Concluding Remarks


18. Appendix 1: Tabulated Data


19. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415




Recommended Comments

There are no comments to display.

Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...